Press Releases
January 7, 2002
Xanodyne Acquires Drug Enhancement Company of America, LLC
Florence, KY — January 7, 2002 — Xanodyne™ Pharmacal,™ Inc. announced today that it has acquired Drug Enhancement Company of America, LLC (DECA), a privately held pharmaceutical product development company.
Xanodyne Pharmacal, Inc. is a branded specialty pharmaceutical company focused in the therapeutic areas of oncology, hematology, and pain management. Xanodyne currently markets AMICAR® (Aminocaproic Acid), Leucovorin Calcium, and a potent cytotoxic drug for cancer treatments. In addition, it has several novel products in its developmental pipeline.
Roger Griggs, Chairman of the Board and CEO of Xanodyne, commented, "The acquisition of DECA does several things for us. First, we obtain access to an exciting, near-term pipeline of pharmaceutical and medical device products that will complement Xanodyne's strategic direction. Second, we gain outstanding expertise and talented employees from DECA. We're very excited about this acquisition. I believe this adds tremendous value to the Company and will enhance our ability to introduce new oncolytics and pain management products into the market."
"This acquisition makes a great deal of sense," stated Jim Young, PhD, President of DECA. "DECA had developed a robust pipeline and hired very capable people. We feel both will integrate well into Xanodyne. The acquisition will accelerate the development and commercialization timelines significantly for both DECA and Xanodyne projects." As part of the transaction, Jim Young, PhD, will serve as Vice President of Product Development and Professional Services at Xanodyne. Keith Moore, PharmD, will direct Medical Affairs and product development activities.